Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 2:11:2040620720914490.
doi: 10.1177/2040620720914490. eCollection 2020.

PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma

Noemie Lang  1 , Michael Crump  2
Affiliations
Review

PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma

Noemie Lang et al. Ther Adv Hematol. .

Abstract

Recent results of randomized phase III studies of FDG-PET-adapted therapy for advanced Hodgkin lymphoma (HL) have clearly demonstrated benefit to alteration of treatment according to interim response, in particular regarding reducing toxicity while maintaining efficacy. However, these studies have differences in design including initial chemotherapy regimen, PET response criteria, patient populations enrolled, and inclusion of radiation, and report different results regarding efficacy and toxicities, which makes cross-trial comparisons difficult. Practitioners are presented with deciding which of these approaches will provide the optimum outcome, balancing toxicity and efficacy, and for which patient with advanced-stage HL. This review summarizes the observations reported from these trials and provides context to help guide physicians and patients in treatment decisions for advanced HL.

Keywords: FDG-PET; hodgkin lymphoma; interim; randomized; toxicity.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author(s) declare that there is no conflict of interest.

References

    1. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin’s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009; 27: 5390–5396. - PubMed
    1. Gordon L, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013; 31: 684–691. - PMC - PubMed
    1. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607–614. - PubMed
    1. Carde P, Karrasch M, Fortpied C, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score >/= 3, high-risk hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol 2016; 34: 2028–2036. - PubMed
    1. Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in Untreated patients with advanced hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 2016; 34: 1175–1181. - PubMed

LinkOut - more resources